Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (263) Arrow Down
Filter Results: (263) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,020)
    • Faculty Publications  (263)

    Show Results For

    • All HBS Web  (1,020)
      • Faculty Publications  (263)

      DrugRemove Drug →

      ← Page 12 of 263 Results →

      Are you looking for?

      →Search All HBS Web
      • February 1998 (Revised March 2003)
      • Teaching Note

      Eli Lilly and Company: Drug Development Strategy (A) and (B) TN

      By: Stefan H. Thomke and Ashok Nimgade
      Teaching Note for (9-698-010) and (9-698-026). View Details
      Citation
      Purchase
      Related
      Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (A) and (B) TN." Harvard Business School Teaching Note 698-033, February 1998. (Revised March 2003.)
      • February 1998 (Revised October 1998)
      • Background Note

      Note on New Drug Development in the United States

      By: Stefan H. Thomke and Ashok Nimgade
      An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details
      Keywords: Product Development; Research and Development; Health; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Thomke, Stefan H., and Ashok Nimgade. "Note on New Drug Development in the United States." Harvard Business School Background Note 698-028, February 1998. (Revised October 1998.)
      • December 1997 (Revised September 2002)
      • Supplement

      Eli Lilly and Company: Drug Development Strategy (B)

      By: Stefan H. Thomke and Ashok Nimgade
      Supplements the (A) case. View Details
      Citation
      Purchase
      Related
      Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (B)." Harvard Business School Supplement 698-026, December 1997. (Revised September 2002.)
      • October 1997 (Revised September 2003)
      • Case

      Eli Lilly and Company: Drug Development Strategy (A)

      By: Stefan H. Thomke, Ashok Nimgade and Paul Pospisil
      Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug... View Details
      Keywords: Chemicals; Finance; Innovation and Invention; Time Management; Markets; Product Development; Organizations; Business Processes; Problems and Challenges; Business and Stakeholder Relations; Competition; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Thomke, Stefan H., Ashok Nimgade, and Paul Pospisil. "Eli Lilly and Company: Drug Development Strategy (A)." Harvard Business School Case 698-010, October 1997. (Revised September 2003.)
      • August 1997
      • Article

      Preventable Adverse Drug Events in Hospitalized Patients: A Comparative Study of Intensive Care and General Care Units

      By: D. J. Cullen, J. Sweitzer, D. W. Bates, E. Burdick, A. Edmondson and L. L. Leape
      Keywords: Health; Information
      Citation
      Find at Harvard
      Related
      Cullen, D. J., J. Sweitzer, D. W. Bates, E. Burdick, A. Edmondson, and L. L. Leape. "Preventable Adverse Drug Events in Hospitalized Patients: A Comparative Study of Intensive Care and General Care Units." Critical Care Medicine 25, no. 8 (August 1997): 1289–1297.
      • September 1996
      • Case

      Food and Drug Administration: Business as Unusual at CDER

      By: Steven C. Wheelwright and James Leonard
      Keywords: Government Administration; Food and Beverage Industry; Pharmaceutical Industry
      Citation
      Find at Harvard
      Related
      Wheelwright, Steven C., and James Leonard. "Food and Drug Administration: Business as Unusual at CDER." Harvard Business School Case 697-022, September 1996.
      • 1996
      • Chapter

      The Determinants of Research Productivity in Ethical Drug Discovery

      By: Rebecca M. Henderson and Ian Cockburn
      Keywords: Ethics; Health Testing and Trials; Research and Development; Performance Productivity; Pharmaceutical Industry
      Citation
      Related
      Henderson, Rebecca M., and Ian Cockburn. "The Determinants of Research Productivity in Ethical Drug Discovery." In Competitive Strategies in the Pharmaceutical Industry, edited by Robert B. Helms. Washington, D.C.: AEI Press, 1996.
      • Article

      Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research

      By: Rebecca M. Henderson and Iain Cockburn
      Keywords: Research and Development; Health; Size
      Citation
      Find at Harvard
      Read Now
      Related
      Henderson, Rebecca M., and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001): 32–59.
      • spring 1996
      • Article

      Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery

      By: Rebecca M. Henderson and Ian Cockburn
      Keywords: Research; Product; Health
      Citation
      Find at Harvard
      Read Now
      Related
      Henderson, Rebecca M., and Ian Cockburn. "Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery." RAND Journal of Economics 27, no. 1 (spring 1996): 32–59.
      • January 1996
      • Case

      Biogen, Inc.: rBeta Interferon Manufacturing Process Development

      By: Steven C. Wheelwright
      Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
      Keywords: Learning; Technological Innovation; Management Analysis, Tools, and Techniques; Product Development; Organizational Change and Adaptation; Projects; Research and Development; Corporate Strategy; Biotechnology Industry
      Citation
      Educators
      Purchase
      Related
      Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
      • fall 1994
      • Article

      Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery

      By: Rebecca M. Henderson and Ian Cockburn
      Keywords: Investment; Competition; Ethics; Health
      Citation
      Read Now
      Related
      Henderson, Rebecca M., and Ian Cockburn. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery." Journal of Economics & Management Strategy 3, no. 3 (fall 1994): 481–519.
      • Article

      Measuring Competence? Exploring Firm Effects in Drug Discovery

      By: Rebecca M. Henderson and Ian Cockburn
      Keywords: Measurement and Metrics; Competency and Skills; Health
      Citation
      Find at Harvard
      Read Now
      Related
      Henderson, Rebecca M., and Ian Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Strategic Management Journal 15 (Winter 1994): 63–84. (Winner of Dan and Mary Lou Schendel Best Paper Prize To honor substantial work published in the Strategic Management Journal presented by Strategic Management Society​.)
      • 1994
      • Article

      The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery

      By: Rebecca M. Henderson
      Keywords: Innovation and Invention; Health; Integration
      Citation
      Find at Harvard
      Read Now
      Related
      Henderson, Rebecca M. "The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery." Industrial and Corporate Change 3, no. 3 (1994): 607–630.
      • November 1993 (Revised January 2006)
      • Supplement

      Beech-Nut Nutrition Corporation (B)

      By: Lynn S. Paine
      Officials of the U.S. Food and Drug Administration (FDA) must decide whether to refer the Beech-Nut apple juice case to the Justice Department for criminal prosecution, and if so, whether to recommend prosecution of individual executives or of the company only. View Details
      Keywords: Crime and Corruption; Decisions; Cases; Law; Management; Food and Beverage Industry
      Citation
      Purchase
      Related
      Paine, Lynn S. "Beech-Nut Nutrition Corporation (B)." Harvard Business School Supplement 394-103, November 1993. (Revised January 2006.)
      • September 1993
      • Case

      Manufacturing at ALZA: The Right Prescription? (A)

      By: Dorothy A. Leonard
      ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
      Keywords: Business or Company Management; Technological Innovation; Innovation and Management; Growth and Development Strategy; Problems and Challenges; Production; Research and Development; Organizational Change and Adaptation; Pharmaceutical Industry; Medical Devices and Supplies Industry
      Citation
      Find at Harvard
      Related
      Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
      • September 1993
      • Supplement

      Manufacturing at ALZA: The Right Prescription? (B)

      By: Dorothy A. Leonard
      ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
      Keywords: Experience and Expertise; Decision Choices and Conditions; Patents; Production; Pharmaceutical Industry; Medical Devices and Supplies Industry
      Citation
      Find at Harvard
      Related
      Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (B)." Harvard Business School Supplement 694-020, September 1993.
      • September 1993
      • Supplement

      Manufacturing at ALZA: The Right Prescription? (C)

      By: Dorothy A. Leonard
      ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
      Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry
      Citation
      Find at Harvard
      Related
      Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
      • June 1993
      • Case

      Boston Fights Drugs

      By: V. Kasturi Rangan
      Keywords: Social Issues; Boston
      Citation
      Educators
      Purchase
      Related
      Rangan, V. Kasturi. "Boston Fights Drugs." Harvard Business School Multimedia/Video Case 593-517, June 1993.
      • April 1993 (Revised October 1995)
      • Case

      ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

      By: Josh Lerner and Peter Tufano
      To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
      Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Medical Devices and Supplies Industry
      Citation
      Educators
      Purchase
      Related
      Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)
      • March 1993
      • Supplement

      Burroughs Wellcome and AZT (B)

      By: Willis M. Emmons III
      Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
      Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
      Citation
      Purchase
      Related
      Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
      • ←
      • 12
      • 13
      • 14
      • →

      Are you looking for?

      →Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.